BI Finds Right Fit For Digital Therapeutic Partnership With Click
Executive Summary
Deal Snapshot: The firms are partnering on a digital therapeutic for schizophrenia in a deal potentially worth $500m.
You may also be interested in...
Boehringer Marches On In Mental Health With Sosei Heptares Pact
The family-owned German firm's legacy lies in the cardiometabolic space but it has been building a pipeline across a range of neuropsychiatric diseases. The collaboration with Sosei Heptares, which has been sealed with a upfront payment of €25m, will focus on schizophrenia.
Profile: Boehringer’s Andersen On Volleyball And Leadership Learnings, Storytelling
Boehringer Ingelheim’s Head of Human Pharma Regions, Timmo Rousku Andersen shares with Scrip glimpses of his life and professional journey including distinct parallels between sports and leadership against the backdrop of the wider commercialization efforts for blockbuster therapy Jardiance.
Beyond Pill Sensors, Digital Tech Can Provide Insights On How Patients Use Drugs
During a panel at the 2022 BioFuture conference, panelists talked about how digital technology can provide data about drugs and devices on the market or in clinical trials.